Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review

Annals of Hematology

Volumn 96, Issue 8, 2017, Pages 1241-1251

  Lin, Molly ^a   Park, Sujin ^a   Hayden, Anna ^a   Giustini, Dean ^a   Trinkaus, Martina ^b   Pudek, Morris ^a   Mattman, Andre ^c   Schneider, Marion ^d   Chen, Luke Y C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Hemophagocytic lymphohistiocytosis; Hemophagocytic syndrome; Interleukin 2 receptor alpha subunit; Macrophage activation syndrome; Soluble CD25; Soluble interleukin 2 receptor

Indexed keywords

BETA 2 MICROGLOBULIN; CD163 ANTIGEN; FERRITIN; FOLLISTATIN; FOLLISTATIN LIKE PROTEIN 1; FRACTALKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; INTERLEUKIN 2 RECEPTOR;

ACUTE LIVER FAILURE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE MARKER; HEMOPHAGOCYTIC SYNDROME; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LANGERHANS CELL HISTIOCYTOSIS; LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; BLOOD; CHILD; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; PRESCHOOL CHILD; SOLUBILITY;

BIOMARKERS; CHILD; CHILD, PRESCHOOL; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; SENSITIVITY AND SPECIFICITY; SOLUBILITY;

EID: 85018697381     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-017-2993-y     Document Type: Review

References (116)

1. Fujiwara F, Hibi S, Imashuku S (1993) Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol Oncol 15:92–98
2. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL (2011) How I treat hemophagocytic lymphohistiocytosis. Blood 118:4041–4052
3. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U (1991) Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78:2918–2922
4. Bodley SR, Robb-Smith A (1939) Histiocytic medullary reticulocytosis. Lancet 234:194–198
5. Emile JF, Abla O, Fraitag S et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681
6. Lehmberg K, Nichols KE, Henter JI et al (2015) Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100:997–1004
7. Ravelli A, Minoia F, Davi S et al (2016) Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol (68):566–576
8. Hayden A, Park S, Giustini D, Lee AY, Chen LY (2016) Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev 30:411–420
9. Kleynberg RL, Schiller GJ (2012) Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol 10:726–732
10. Janka GE (2012) Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 63:233–246
11. Castillo L, Carcillo J (2009) Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 10:387–392
12. Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12:259–268
13. Henter JI, Horne A, Arico M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131
14. Fardet L, Galicier L, Lambotte O et al (2014) Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66:2613–2620
15. Ravelli A, Magni-Manzoni S, Pistorio A et al (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 146:598–604
16. Hejblum G, Lambotte O, Galicier L et al (2014) A web-based Delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients. PLoS One 9:e94024
17. Tamamyan GN, Kantarjian HM, Ning J et al (2016) Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes. Cancer 122:2857–2866
18. Henter JI, Elinder G, Ost A (1991) Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 18:29–33
19. Tsuda H (1997) Hemophagocytic syndrome (HPS) in children and adults. Int J Hematol 65:215–226
20. Imashuku S (1997) Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol 66:135–151
21. Takagi S, Masuoka K, Uchida N et al (2009) High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol 147:543–553
22. Olejniczak K, Kasprzak A (2008) Biological properties of interleukin 2 and its role in pathogenesis of selected diseases—a review. Med Sci Monit 14:RA179–RA189
23. Smith KA (1988) Interleukin-2: inception, impact, and implications. Science 240:1169–1176
24. Coca A, Bundy KW, Marston B, Huggins J, Looney RJ (2009) Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol 132:10–18
25. Rubin LA, Kurman CC, Fritz ME et al (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177
26. Rubin LA, Snow KM, Kurman CC, Nelson DL, Keystone EC (1990) Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol 17:597–602
27. Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 113, 619–627.
28. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL (1987) Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 139:3802–3807
29. Monsalve-De CF, Romero TA, Estevez J et al (2002) Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol 9:1372–1375
30. Rudman SA, Walkovich K, Price S et al (2013) Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis. Pediatrics 132:e1440–e1444
31. Komp DM, McNamara J, Buckley P (1989) Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 73:2128–2132
32. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta M, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383:1503–1516
33. Akashi K, Hayashi S, Gondo H et al (1994) Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 87:243–250
34. Asano T, Kogawa K, Morimoto A et al (2012) Hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation in children: a nationwide survey in Japan. Pediatr Blood Cancer 59:110–114
35. Beutel G, Wiesner O, Eder M et al (2011) Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care 15:R80–R87
36. Bleesing J, Prada A, Siegel DM et al (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56:965–971
37. Bode SFN, Ammann S, Al-Herz W et al (2015) The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica 100:978–988
38. Chen Y, Wang Z, Luo Z, Zhao N, Yang S, Tang Y (2016) Comparison of Th1/Th2 cytokine profiles between primary and secondary haemophagocytic lymphohistiocytosis. Ital J Pediatr 42:50
39. Duval M, Fenneteau O, Doireau V et al (1999) Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. J Pediatr 134:236–239
40. Fujiwara F, Hibi S, Imashuku S (1993) Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol/Oncol 15:92–98
41. Gao ZY, Li XY, Bhandari V, Li LD, Lan D (2015) Pre-B-cell colony-enhancing factor is markedly elevated in childhood hemophagocytic lymphohistiocytosis. Genet Mol Res 14:5287–5295
42. Gorelik M, Fall N, Altaye M et al (2013) Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 40:1191–1199
43. Honda K, Ohga S, Takada H et al (2000) Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation? Int J Hematol 72:55–60
44. Imashuku S, Hibi S, Tabata Y, Todo S, Ohno T (1999) Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma. Cancer 85:2298–2299
45. Imashuku S, Hibi S, Tabata Y et al (1998) Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 31:131–137
46. Imashuku S, Hibi S, Sako M et al (1998) Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: comparative study of 9 familial and 14 familial inheritance-unproved cases. J Pediatr Hematol Oncol 20:207–214
47. Imashuku S, Hibi S, Fujiwara F, Todo S (1996) Hyper-interleukin (IL)-6-naemia in haemophagocytic lymphohistiocytosis. Br J Haematol 93:803–807
48. Imashuku S, Hibi S, Sako M et al (1995) Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood 86:4706–4707
49. Imashuku S, Ikushima S, Esumi N, Todo S, Saito M (1991) Serum levels of interferon-gamma, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes. Leuk Lymphoma 3:287–292
50. Kasama T, Furuya H, Yanai R et al (2012) Correlation of serum CX3CL1 level with disease activity in adult-onset Still’s disease and significant involvement in hemophagocytic syndrome. Clin Rheumatol 31:853–860
51. Kounami S, Yoshiyama M, Nakayama K et al (2005) Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. Acta Haematol 113:124–129
52. Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G (2013) Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 162:1245–1251
53. Lenert A, Yao Q (2016) Macrophage activation syndrome complicating adult onset Still’s disease: a single center case series and comparison with literature. Semin Arthritis Rheum 45:711–716
54. Schneider EM, Lorenz I, Muller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE (2002) Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 100:2891–2898
55. Marsh RA, Allen CE, McClain KL et al (2013) Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 60:101–109
56. Mazodier K, Marin V, Novick D et al (2005) Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106:3483–3489
57. Mellor-Heineke S, Villanueva J, Jordan MB et al (2013) Elevated granzyme B in cytotoxic lymphocytes is a signature of immune activation in hemophagocytic lymphohistiocytosis. Front Immunol 4:72–79
58. Miyahara M, Sano M, Shibata K et al (2000) B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol 79:378–388
59. Miyazaki T, Kirino Y, Takeno M et al (2010) Serum HO-1 is useful to make differential diagnosis of secondary hemophagocytic syndrome from other similar hematological conditions. Int J Hematol 91:229–237
60. Murohashi I, Yoshida K, Ihara N et al (2006) Serum levels of Thl/Th2 cytokines, angiogenic growth factors, and other prognostic factors in young adult patients with hemophagocytic syndrome. Lab Hematol 12:71–74
61. Ohno T, Ueda Y, Nagai K-i et al (2003) The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas. Int J Hematol 77:286–294
62. Ohno T, Miyake N, Hada S et al (1998) Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma. Cancer 82:1963–1972
63. Otrock ZK, Gonzalez MD, Eby CS (2015) Ehrlichia-induced hemophagocytic lymphohistiocytosis: a case series and review of literature. Blood Cells Mol Dis 55:191–193
64. Otrock ZK, Eby CS (2015) Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 90:220–224
65. Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A (2014) Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis. Int J Rheum Dis 17:261–267
66. Schram AM, Campigotto F, Mullally A et al (2015) Marked hyperferritinemia does not predict for HLH in the adult population. Blood 125:1548–1552
67. Shiraishi A, Ohga S, Doi T et al (2012) Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 59:265–270
68. Sumegi J, Nestheide S, Aronow B et al (2016) MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy. J Allergy Clin Immunol 137:309–312
69. Tabata R, Tabata C (2012) Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndromes. Ann Hematol 91:63–71
70. Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H (2014) A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol 93:821–826
71. Ueda I, Ishii E, Morimoto A, Ohga S, Sako M, Imashuku S (2006) Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr Blood Cancer 46:482–488
72. Wu DX, Wang Z, Wang XL, Lin RR, Liu N, Zhang J (2012) Significance of serum CD25:serum ferritin in the diagnosis of lymphoma-associated hemophagocytic syndrome. J Leuk Lymphoma 31:1–7
73. Yajima N, Wakabayashi K, Odai T et al (2008) Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol 35:1838–1841
74. Yang YQ, Ding CY, Xu J et al (2016) Exploring the role of bone marrow increased FDG uptake on PET/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: a reflection of bone marrow involvement or cytokine storm? Leuk Lymphoma 57:291–298
75. Yasumi T, Hori M, Hiejima E et al (2015) Laboratory parameters identify familial haemophagocytic lymphohistiocytosis from other forms of paediatric haemophagocytosis. Br J Haematol 170:532–538
76. Zhang L, Zhang S, Xu J et al (2011) Significance of soluble interleukin-2 receptor in patients with hemophagocytic lymphohistiocytosis. Leukemia & Lymphoma 52:1360–1362
77. Buchhorn R, Muller C, Manhardt LB, Willaschek C, Schneider EM, Stuth EA (2010) Beta-blocker therapy and hemophagocytic lymphohistiocytosis: a case report. Cardiol Res Pract 912757–912754
78. DiPaola F, Grimley M, Bucuvalas J (2014) Pediatric acute liver failure and immune dysregulation. J Pediatr 164:407–409
79. Faguer S, Vergez F, Peres M et al (2016) Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis. Hematol Oncol 34:55–57
80. Imashuku S, Okuda T, Yoshihara T, Ikushima S, Hibi S (1991) Cytokine levels in aggressive natural killer cell leukaemia and malignant histiocytosis. Br J Haematol 79:132–133
81. Olin RL, Nichols KE, Naghashpour M et al (2008) Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol 83:747–749
82. Tomaske M, Amon O, Bosk A, Handgretinger R, Schneider EM, Niethammer D (2002) Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 38:141–142
83. Amir A, Ling S, Naqvi A et al (2016) Liver transplantation for children with acute liver failure associated with secondary haemophagocytic lymphohistiocytosis. J Hepatol 64:S295–S296
84. Cai Q, Huang HQ, Bai B et al (2013) The serum spectrum of cytokines in patients with NK/T-cell lymphoma and its clinical significance in survival. Blood 122:1759
85. Goldberg B, Muscal E, De Guzman M, Allen C (2015) Development of systemic juvenile idiopathic arthritis manifestations following remission of hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 67:2
86. Nanno S, Koh H, Katayama T. et al. (2015) Plasma levels of presepsin (soluble CD14-subtype) as a novel prognostic marker for hemophagocytic syndrome. In 20th Congress of the European Hematology Association Vienna, Austria, Haematologica, 557.
87. Imashuku S (2002) Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 44:259–272
88. Janka GE, Schneider EM (2004) Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 124:4–14
89. Johnson TS, Villanueva J, Filipovich AH, Marsh RA, Bleesing JJ (2011) Contemporary diagnostic methods for hemophagocytic lymphohistiocytic disorders. J Immunol Methods 364:1–13
90. Weitzman S (2011) Approach to hemophagocytic syndromes. Hematology 2011:178–183
91. Lehmberg K, Ehl S (2013) Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol 160:275–287
92. Madkaikar M, Shabrish S, Desai M (2016) Current updates on classification, diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH). Indian J Pediatr 83:434–443
93. Bryceson YT, Pende D, Maul-Pavicic A et al (2012) A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 119:2754–2763
94. Wu JR, Yuan LX, Ma ZG, Chen XX, Gu L, Gao J (2013) GDF15-mediated upregulation of ferroportin plays a key role in the development of hyperferritinemia in children with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 60:940–945
95. Jordan MB, Hildeman D, Kappler J, Marrack P (2004) An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104:735–743
96. Zoller EE, Lykens JE, Terrell CE et al (2011) Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 208:1203–1214
97. Bracaglia C, de Graaf K, Pires Marafon D et al (2017) Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 76:166–172
98. Schneider EM (2004) Bullfight without killers: interferon rules pathology in HLH. Blood 104:600–601
99. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG (2012) Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76:16–32
100. La Rosee P. (2016) Alleviating the storm: ruxolitinib in HLH. Blood 127:1626–1627
101. Canna SW, Behrens EM (2012) Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin N Am 59:329–344
102. Canna SW, Nigrovic PA (2016) Editorial: 21st century storm chasers: defining macrophage activation syndrome. Arthritis Rheumatol 68:557–560
103. Bien E, Balcerska A (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 13:1–26
104. Witkowska AM (2005) On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediat Inflamm 2005:121–130
105. Kloster BE, John PA, Miller LE et al (1987) Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol 45:440–446
106. Prin L, Plumas J, Gruart V et al (1991) Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome. Blood 78:2626–2632
107. Tomita N, Suzuki T, Miyashita K et al (2016) The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leuk Lymphoma 57:2763–2770
108. Yamaguchi M, Suzuki R, Oguchi M et al (2017) Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol 35:32–39
109. Masaki Y, Dong L, Nakajima A et al (2009) Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. Int J Hematol 89:600–610
110. Umino K, Fujiwara SI, Ito S et al (2017) Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. Leuk Lymphoma 58:316–323
111. Bucuvalas J, Filipovich L, Yazigi N et al (2013) Immunophenotype predicts outcome in pediatric acute liver failure. J Pediatr Gastroenterol Nutr 56:311–315
112. Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB (2015) Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol 192:84–91
113. Mohty M (2007) Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21:1387–1394
114. Hu Y, Turner MJ, Shields J et al (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128:260–270
115. Novimmune SA (2013) Long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), [cited 2017 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02069899.
116. Children’s Hospital Medical Center (2016) Hybrid immunotherapy for hemophagocytic lympho histiocytosis. In: ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01104025. Jan 10, 2016.